- Home
- ZM vs NTRA Comparison
ZM vs NTRA Comparison
Compare ZM & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZM
- NTRA
- Stock Information
- Founded
- ZM 2011
- NTRA 2003
- Country
- ZM United States
- NTRA United States
- Employees
- ZM N/A
- NTRA N/A
- Industry
- ZM Computer Software: Programming Data Processing
- NTRA Medical Specialities
- Sector
- ZM Technology
- NTRA Health Care
- Exchange
- ZM Nasdaq
- NTRA Nasdaq
- Market Cap
- ZM 25.5B
- NTRA 27.0B
- IPO Year
- ZM 2019
- NTRA 2015
- Fundamental
- Price
- ZM $84.51
- NTRA $205.15
- Analyst Decision
- ZM Buy
- NTRA Strong Buy
- Analyst Count
- ZM 26
- NTRA 16
- Target Price
- ZM $91.67
- NTRA $220.38
- AVG Volume (30 Days)
- ZM 2.5M
- NTRA 1.4M
- Earning Date
- ZM 11-24-2025
- NTRA 11-06-2025
- Dividend Yield
- ZM N/A
- NTRA N/A
- EPS Growth
- ZM 35.88
- NTRA N/A
- EPS
- ZM 3.80
- NTRA N/A
- Revenue
- ZM $4,753,621,000.00
- NTRA $2,116,676,000.00
- Revenue This Year
- ZM $6.70
- NTRA $25.70
- Revenue Next Year
- ZM $3.35
- NTRA $15.42
- P/E Ratio
- ZM $22.19
- NTRA N/A
- Revenue Growth
- ZM 3.63
- NTRA 38.17
- 52 Week Low
- ZM $64.41
- NTRA $125.38
- 52 Week High
- ZM $92.80
- NTRA $212.21
- Technical
- Relative Strength Index (RSI)
- ZM 53.19
- NTRA 65.15
- Support Level
- ZM $80.82
- NTRA $182.20
- Resistance Level
- ZM $85.75
- NTRA $212.21
- Average True Range (ATR)
- ZM 2.10
- NTRA 8.09
- MACD
- ZM -0.06
- NTRA 0.00
- Stochastic Oscillator
- ZM 42.71
- NTRA 75.84
About ZM Zoom Video Communications Inc.
Zoom Video Communications provides a communications platform that connects people through video, voice, chat, and content sharing. The company's cloud-native platform enables face-to-face video and connects users across various devices and locations in a single meeting. Zoom, which was founded in 2011 and is headquartered in San Jose, California, serves companies of all sizes from all industries around the world.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.